Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature

被引：2

作者：

Albarran, Victor ^{[1
]}

Chamorro, Jesus ^{[1
]}

Pozas, Javier ^{[1
]}

San Roman, Maria ^{[1
]}

Rosero, Diana Isabel ^{[1
]}

Saavedra, Cristina ^{[1
]}

Gion, Maria ^{[1
]}

Cortes, Alfonso ^{[1
]}

Escalera, Elena ^{[1
]}

Guerra, Eva ^{[1
]}

Lopez Miranda, Elena ^{[1
]}

Fernandez Abad, Maria ^{[1
]}

Martinez Janez, Noelia ^{[1
]}

机构：

[1] Ramon & Cajal Univ Hosp, Med Oncol Dept, Madrid, Spain

来源：

FRONTIERS IN ONCOLOGY | 2023年 / 13卷

关键词：

breast cancer; BRCA; germline; PARP inhibitors; olaparib; talazoparib; PARP INHIBITORS; DOUBLE-BLIND; MAINTENANCE THERAPY; OLAPARIB; OVARIAN; CARBOPLATIN; CHEMOTHERAPY; MULTICENTER; PALBOCICLIB; PACLITAXEL;

D O I：

10.3389/fonc.2023.1158981

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PARP inhibitors are progressively becoming a part of our therapeutic arsenal against BRCA-defective tumors, because of their capacity to induce synthetic lethality in cells with a deficiency in the homologous recombination repair system. Olaparib and talazoparib have been approved for metastatic breast cancer in carriers of germline BRCA mutations, which are found in approximately 6% of patients with breast cancer. We report the case of a patient with metastatic breast cancer, carrier of a germline mutation in BRCA2, with a complete response to first-line treatment with talazoparib, maintained after 6 years. To the best of our knowledge, this is the longest response reported with a PARP inhibitor in a BRCA-mutated tumor. We have made a review of literature, regarding the rationale for PARP inhibitors in carriers of BRCA mutations and their clinical relevance in the management of advanced breast cancer, as well as their emerging role in early stage disease, alone and in combination with other systemic therapies.

引用

页数：7

共 48 条

[1]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21609, 10.3322/caac.21492]

[2] Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Coleman, Robert L. ;

Oza, Amit M. ;

Lorusso, Domenico ;

Aghajanian, Carol ;

Oaknin, Ana ;

Dean, Andrew ;

Colombo, Nicoletta ;

Weberpals, Johanne, I ;

Clamp, Andrew ;

Scambia, Giovanni ;

Leary, Alexandra ;

Holloway, Robert W. ;

Amenedo Gancedo, Margarita ;

Fong, Peter C. ;

Goh, Jeffrey C. ;

O'Malley, David M. ;

Armstrong, Deborah K. ;

Garcia-Donas, Jesus ;

Swisher, Elizabeth M. ;

Floquet, Anne ;

Konecny, Gottfried E. ;

McNeish, lain A. ;

Scott, Clare L. ;

Cameron, Terri ;

Maloney, Lara ;

Isaacson, Jeff ;

Goble, Sandra ;

Grace, Caroline ;

Harding, Thomas C. ;

Raponi, Mitch ;

Sun, James ;

Lin, Kevin K. ;

Giordano, Heidi ;

Ledermann, Jonathan A. .

LANCET, 2017, 390 (10106) :1949-1961

[3] A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status [J].

Collins, Jenna M. ;

Nordstrom, Beth L. ;

McLaurin, Kimmie K. ;

Dalvi, Tapashi B. ;

McCutcheon, Susan C. ;

Bennett, James C. ;

Murphy, Brian R. ;

Singhal, Puneet K. ;

McCrea, Charles ;

Shinde, Reshma ;

Briceno, Josefa M. .

ONCOLOGY AND THERAPY, 2021, 9 (02) :575-589

[4] Pathologic Response and Long-Term Follow-up in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy A Comparison Between Classifications and Their Practical Application [J].

Corben, Adriana D. ;

Abi-Raad, Rita ;

Popa, Ion ;

Teo, Clarence H. Y. ;

Macklin, Eric A. ;

Koerner, Frederick C. ;

Taghian, Alphonse G. ;

Brachtel, Elena F. .

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2013, 137 (08) :1074-1082

[5] Olaparib for Metastatic Castration-Resistant Prostate Cancer [J].

de Bono, J. ;

Mateo, J. ;

Fizazi, K. ;

Saad, F. ;

Shore, N. ;

Sandhu, S. ;

Chi, K. N. ;

Sartor, O. ;

Agarwal, N. ;

Olmos, D. ;

Thiery-Vuillemin, A. ;

Twardowski, P. ;

Mehra, N. ;

Goessl, C. ;

Kang, J. ;

Burgents, J. ;

Wu, W. ;

Kohlmann, A. ;

Adelman, C. A. ;

Hussain, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22) :2091-2102

[6] Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial [J].

del Campo, Josep M. ;

Matulonis, Ursula A. ;

Malander, Susanne ;

Provencher, Diane ;

Mahner, Sven ;

Follana, Philippe ;

Waters, Justin ;

Berek, Jonathan S. ;

Woie, Kathrine ;

Oza, Amit M. ;

Canzler, Ulrich ;

Gil-Martin, Marta ;

Lesoin, Anne ;

Monk, Bradley J. ;

Lund, Bente ;

Gilbert, Lucy ;

Wenham, Robert M. ;

Benigno, Benedict ;

Arora, Sujata ;

Hazard, Sebastien J. ;

Mirza, Mansoor R. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) :2968-+

[7] Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016 [J].

Deluche, Elise ;

Antoine, Alison ;

Bachelot, Thomas ;

Lardy-Cleaud, Audrey ;

Dieras, Veronique ;

Brain, Etienne ;

Debled, Marc ;

Jacot, William ;

Mouret-Reynier, Marie Ange ;

Goncalves, Anthony ;

Dalenc, Florence ;

Patsouris, Anne ;

Ferrero, Jean Marc ;

Levy, Christelle ;

Lorgis, Veronique ;

Vanlemmens, Laurence ;

Lefeuvre-Plesse, Claudia ;

Mathoulin-Pelissier, Simone ;

Petit, Thierry ;

Uwer, Lionel ;

Jouannaud, Christelle ;

Leheurteur, Marianne ;

Lacroix-Triki, Magali ;

Courtinard, Coralie ;

Perol, David ;

Robain, Mathieu ;

Delaloge, Suzette .

EUROPEAN JOURNAL OF CANCER, 2020, 129 :60-70

[8] Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer [J].

Dent, Rebecca A. ;

Lindeman, Geoffrey J. ;

Clemons, Mark ;

Wildiers, Hans ;

Chan, Arlene ;

McCarthy, Nicole J. ;

Singer, Christian F. ;

Lowe, Elizabeth S. ;

Watkins, Claire L. ;

Carmichael, James .

BREAST CANCER RESEARCH, 2013, 15 (05)

[9] Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer [J].

Desnoyers, A. ;

Nadler, M. ;

Wilson, B. E. ;

Stajer, S. ;

Amir, E. .

NPJ BREAST CANCER, 2022, 8 (01)

[10] Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Dieras, Veronique ;

Han, Hyo S. ;

Kaufman, Bella ;

Wildiers, Hans ;

Friedlander, Michael ;

Ayoub, Jean-Pierre ;

Puhalla, Shannon L. ;

Bondarenko, Igor ;

Campone, Mario ;

Jakobsen, Erik H. ;

Jalving, Mathilde ;

Oprean, Cristina ;

Palacova, Marketa ;

Park, Yeon Hee ;

Shparyk, Yaroslav ;

Yanez, Eduardo ;

Khandelwal, Nikhil ;

Kundu, Madan G. ;

Dudley, Matthew ;

Ratajczak, Christine K. ;

Maag, David ;

Arun, Banu K. .

LANCET ONCOLOGY, 2020, 21 (10) :1269-1282

← 1 2 3 4 5 →